Influenza Treatment in the Primary Care Setting
Although the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention estimates that influenza has resulted in between 9.2 million and 35.6 million illnesses, 140,000 to 710,000 hospitalizations, and 12,000 to 56,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation of the impact associated with a pandemic. Antivirals with different targets and mechanisms of action provide multiple therapeutic options and hold promise for improving treatment effectiveness, especially in pediatric and adolescent patients. In this continuing education activity, an expert clinician discusses the optimal ways to diagnose and treat influenza.
The intended audience for this activity is primary care physicians, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with or at risk for influenza.
Upon successful completion of this activity, participants should be better able to:
- Apply new evidence into practice regarding the use of diagnostic testing, treatment, and chemoprophylaxis for people with or at risk for influenza.
- Incorporate the use of antiviral agents into practice based on their ability to reduce transmission, as well as treat people with influenza who are at normal or high risk for complications.
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Dr. Russell discloses the following:
Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur
Conflict of Interest Disclosure Policy
In accordance with the Accreditation Council for Continuing Medical Education and American Nurses Credentialing Center’s Commission on Accreditation’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.
Accredited Provider Disclosure
Vindico Medical Education Staff: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP has no relevant financial relationships to disclose.
Linda A. Giarraputo PA-C has no relevant financial relationships to disclose.
Nurse Planner Disclosures
Chad Rittle DNP, MPH, RN, FAAOHN has no relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ, discloses the following:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson
Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
This continuing education activity is provided by Vindico Medical Education.
AMA PRA Category 1 CreditTM
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ANCC Contact Hours
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Vindico Medical Education will provide 0.75 contact hours for nurses.
AANP Contact Hours
This activity is approved for 0.75 contact hour(s) of continuing education (which includes 0.67 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20064282. This activity was planned in accordance with AANP Accreditation Standards and Policies.
AAPA Category I Credit
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid from 6/30/2020 to 6/30/2021 . PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-200543.
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
This course is offered through myCME. To take this course you will be redirected to myCME's website. You must have an account with myCME in order to complete this activity.
Mocingbird continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!